A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.

@article{Lendvai2014AP2,
  title={A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.},
  author={Nikoletta K. Lendvai and Patrick Hilden and Sean M. Devlin and Heather Landau and Hani Hassoun and Alexander M Lesokhin and Ioanna Tsakos and Kaitlyn Redling and Guenther Koehne and David J. Chung and Wendy L. Schaffer and Sergio A Giralt},
  journal={Blood},
  year={2014},
  volume={124 6},
  pages={899-906}
}
Standard carfilzomib (20 mg/m(2) cycle 1, 27 mg/m(2) thereafter; 2- to 10-minute infusion) is safe and effective in relapsed or refractory multiple myeloma (R/RMM). We report phase 2 results of carfilzomib 20 mg/m(2) on days 1 to 2 of cycle 1, 56 mg/m(2) thereafter (30-minute infusion), in R/RMM with the option of adding dexamethasone (20 mg) for suboptimal response/progression. Forty-four patients enrolled, all having prior bortezomib and immunomodulatory drugs and a median of 5 prior regimens… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 6 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

Fatal pulmonary hemorrhage after carfilzomib treatment in multiple myeloma

Annals of Hematology • 2015
View 5 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell BLOOD, 7 AUGUST 2014 x VOLUME 124, NUMBER 6 CARFILZOMIB 56 mg/m2 IN RELAPSED/REFRACTORY MYELOMA

KS Baker, KK Ness, J Steinberger
For personal use only. on September • 2016
View 1 Excerpt

Similar Papers

Loading similar papers…